A Comparative Analysis of Anticancer Drug Appraisals Including Managed Entry Agreements in South Korea and England.

England relies on economic evaluation, with increasing use of data collection agreements, in contrast with Korea's new procedure exempting companies from providing economic evaluation. While there is possibility for international cooperation in the assessment of clinical evidence, transferability issues exist, particularly with regard to economic evidence.